Expanding the Efflux In Vitro Assay Toolbox: A CRISPR-Cas9 Edited MDCK Cell Line with Human BCRP and Completely Lacking Canine MDR1

The Breast Cancer Resistance Protein (BCRP) is a key transporter in drug efflux and drug-drug interactions. However, endogenous expression of Multidrug Resistance Protein 1 (MDR1) confounds the interpretation of BCRP-mediated transport in in vitro models. Here we used a CRISPR-Cas9 edited Madin-Darby canine kidney (MDCK) II cell line (MDCKcMDR1-KO) for stable expression of human BCRP (hBCRP) with no endogenous canine MDR1 (cMDR1) expression (MDCK-hBCRP(cMDR1-KO)). Targeted quantitative proteomics verified expression of hBCRP, and global analysis of the entire proteome corroborated no or very low background expression of other drug transport proteins or metabolizing enzymes. This new cell line, had similar proteome like MDCKcMDR1-KO and a previously established, corresponding cell line overexpressing human MDR1 (hMDR1), MDCK-hMDR1(cMDR1-KO). Functional studies with MDCKhBCRP(cMDR1-KO) confirmed high hBCRP activity. The MDCK-hBCRP(cMDR1-KO) cell line together with the MDCK-hMDR1(cMDR1-KO) easily and accurately identified shared or specific substrates of the hBCRP and the hMDR1 transporters. These cell lines offer new, improved in vitro tools for the assessment of drug efflux and drug-drug interactions in drug development. (C) 2020 American Pharmacists Association (R). Published by Elsevier Inc.

Automated summary

A new MDCK-hBCRP(cMDR1-KO) cell line was established using CRISPR-Cas9 editing for studying drug efflux and drug-drug interactions. The cell line was validated for high expression of hBCRP activity through proteomics and functional studies.